Psychedelics for anxiety disorders: Challenges and opportunities
Fundamental Research July 16, 2025 DOI: 10.1016/j.fmre.2025.07.008 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Interventions | 2 5-dimethoxy-4-iodoamphetamine (DOI) |
| Topics | Anxiety |
| Key findings | The 5-HT 2A receptor in ventral hippocampal parvalbumin interneurons mediates the acute anxiolytic effects of DOI. |
Abstract
A recent study published in Neuron by Tiwari et al . identified the critical role of 5-HT 2A receptor in ventral hippocampal parvalbumin (PV) interneurons (INs) in mediating the acute anxiolytic effects of the serotonergic psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI). This study not only advances psychedelic neuropharmacology but also provides a robust framework for developing novel rapid-acting therapeutics for anxiety disorders [ 1 ].